The Venture Codex Logo

The Venture Codex

Level 8 Ventures

S Main St, Ann Arbor, MI, 48104, United States

Overview

We live in an age characterized by accelerating advances in biochemistry, materials science, robotics and artificial intelligence. These enabling technologies are being combined in novel ways to create solutions that are cleaner, smarter and more sustainable than those they displace. Level Eight invests time and capital in the outstanding teams driving this disruption.

Total investments
2
Lead investments
2
Investments · 12mo
0
Active investors
1

Sector focus

  • Venture Capital
Visit website

Investment portfolio

  • SpinTech MRI

    Led · Series A · Jul 2022

    SpinTech MRI is a Bingham Farms, Michigan-based developer of the FDA-cleared STAGE (STrategically Acquired Gradient Echo) quantitative MRI platform. STAGE integrates between the MRI scanner and PACS and does not alter radiologists' familiar workflows or desktop workspaces. The platform standardizes image data across scanner brands and models, and its rapid sequencing and processing reduces acquisition time for comprehensive brain imaging by an average of 40 percent. On 3T systems STAGE can acquire 16 brain imaging contrasts — including 10 enhanced qualitative outputs and 6 quantitative outputs — in about 5 minutes. The technology is used to improve diagnosis and monitoring for Parkinson’s, Alzheimer’s, dementia, multiple sclerosis, TBI, stroke, cerebral microbleeds and other neurological diseases and is deployed at more than 50 hospitals and institutions, including Yale School of Medicine. The company recently raised $6.5M in Series A financing and intends to use the funds to expand deployments of STAGE for neurologists, radiologists and researchers.

  • Pathware

    Led · Series A · Apr 2022

    Pathware develops integrated hardware and software to bring digital pathology from the central laboratory to the point-of-care. The company's core product pairs imaging hardware with software to enable decentralized pathology workflows. Pathware intends to use its newly raised funds to expand the team and to submit its integrated hardware and software system to the FDA for clearance. The company announced a $7M Series A to support these efforts. Pathware is led by newly named CEO TJ Meyer, who previously led global marketing, strategy, clinical support, and business development at Veran Medical Technologies. During his tenure at Veran, the company grew revenues from $2 million to $30 million and was acquired by Olympus in December 2020.

Team